Lp-PLA2: an emerging biomarker of coronary heart disease
- 9 January 2002
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 2 (1), 17-22
- https://doi.org/10.1586/14737159.2.1.17
Abstract
Cardiovascular disease is the leading cause of death in most industrialized countries. However, the diagnosis and management of coronary heart disease is far from optimal. Lipoprotein-associated phospholipase A2 (Lp-PLA2), also known as platelet-activating factor acetylhydrolase, is an enzyme that hydrolyses oxidized phospholipids and is primarily associated with low-density lipoprotein. Discussed in this review is the accumulating evidence supporting the view that Lp-PLA2 is a potential biomarker of coronary heart disease and plays and an important proinflammatory role in the progression of atherosclerosis. A new ELISA method for the quantitative measurement of Lp-PLA2 mass in human plasma developed by diaDexus, Inc. is presented. Furthermore, potential clinical applications of Lp-PLA2 mass measurements are proposed.Keywords
This publication has 12 references indexed in Scilit:
- Lipoprotein-associated PLA2 inhibition — a novel, non-lipid lowering strategy for atherosclerosis therapyIl Farmaco, 2001
- Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery diseaseAtherosclerosis, 2000
- Circulating Levels of Secretory Type II Phospholipase A 2 Predict Coronary Events in Patients with Coronary Artery DiseaseCirculation, 1999
- HDL, its enzymes and its potential to influence lipid peroxidationAtherosclerosis, 1995
- The oxidation hypothesis of atherosclerosisThe Lancet, 1994
- Variation in plasma platelet-activating factor degradation and serum lipids after acute myocardial infarctionCoronary Artery Disease, 1993
- Plasma platelet-activating factor degradation in patients with severe coronary artery diseaseClinical Science, 1992
- Increased activity of the platelet-activating factor acetylhydrolase in plasma low density lipoprotein from patients with essential hypertensionProstaglandins, 1989
- The degradation of platelet-activating factor in serum and its discriminative value in atherosclerotic patientsThrombosis Research, 1988
- Activity of platelet-activating factor (PAF) acetylhydrolase in plasma from patients with ischemic cerebrovascular diseaseProstaglandins, 1988